Evercyte bringing latest cell-based advances to BIO-Europe Hamburg

Vienna, Austria: – Innovative biotech manufacturer Evercyte GmbH will be bringing details of its latest cell-based products and services to Europe’s key pharma partnering event, BIO-Europe.

This is a return to BIO-Europe for Evercyte, who attended the previous conference in Copenhagen.

Preclinical testing and assay development

The Evercyte team, headed by CEO Otto Kanzler, will emphasize the laboratory’s preclinical testing assets, along with its services in assay and cell line development, production, purification and characterization of extracellular vesicles (EVs) and generation of induced pluripotent stem (iPS) cells from urine.

The team will also showcase Evercyte’s impressive product portfolio of telomerized cell lines and iPS cells

Advanced iPS capabilities

Evercyte has made significant breakthroughs in the development of ‘B-different’ human patient-specific B-cells from urine-derived induced pluripotent stem cells (IPS).

Its joint development project with the Children’s Cancer Research Institute in Vienna had created a platform to advance the science of generating B-cells for basic research and personalized cell based therapies.

Combined presence

The Evercyte attendance at BIO-Europe Hamburg is part of a larger presence that also involves partner companies TAmiRNA GmbH and Phoenestra GmbH, reaching out to pharma and biotech industry decision makers, along with research companies in the cell biology field.

“Once again, we plan to make full use of the superb EBD partneringONE network to reach out to prospective customers and partners,” said Otto Kanzler.

About Evercyte

Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; human relevant and standardizable cell models for pre-clinical testings, induced pluripotent stem cells and telomerized cells, with fully documented history and high quality for production of extracellular vesicles for clinical applications, in vitro bioassays including potency assays for extracellular vesicles.

Evercyte has also become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.

Founded in 2011, the Vienna-based company successfully offers tools and the know-how necessary for the establishment of standardized high-throughput target identification and drug screening strategies, for toxicity studies, or for efficacy testing from statistically relevant numbers of donors. In addition, Evercyte now also focuses on using telomerized cells as cell factories. Further information at http://www.evercyte.com.

About BIO-Europe 2019

The BIO-Europe^® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2019 is a three-day event opening November 11 at the Messe Hamburg international expo center.

BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw almost 4,500 industry attendees from nearly 60 countries, representing more than 2,300 companies for three days of high level networking.

Partnering at BIO-Europe 2019 is powered by EBD Group’s partneringONE^®, the industry’s most advanced networking system, which enables participants to identify and pre-arrange private one-to-one meetings with multiple company targets.

More information at: https://www.tradefairdates.com/BIO-Europe-M13093/Hamburg.html.